Supporting Two COVID-19 Clinical Studies in Sub-Saharan Africa

We were delighted to receive a $288,000 grant to support a clinical study in Sub-Saharan Africa in efforts to find a  treatment for Coronavirus. This was awarded from the COVID-19 Therapeutics Accelerator, an initiative by the Bill & Melinda Gates Foundation, Wellcome and Mastercard.

Donation to support COVID-19 testing      in clinical laboratories

Almac Group, together with other companies in the BioPharmaChem Ireland network, provided financial support towards the cost of a key raw material in the manufacture of Lysis buffer a critical reagent required for Covid-19 testing. The buffer, will enable support of Covid-19 testing in clinical laboratories in the Republic of Ireland and Northern Ireland.

Supporting multiple programs to accelerate COVID-19 Coronavirus treatment  

We are proud to be supporting 34 separate crucial research projects into Covid-19 treatment options for a variety of global pharmaceutical, biotech and research institutions.This is being provided by a range of services including analytical services, peptide development, expedited interactive response technology (IRT) support and clinical trial manufacturing, packaging and distribution on projects involving vaccines and potential treatments for symptoms of the coronavirus.

Supporting our clients

Introducing Simplify^TM, an Advanced IRT Solution Enabling Faster Clinical Trials Start-up

2018-19 Figures show Almac Group's Turnover Increased by £85M to £634M  

Almac Group has reported an £85.4 million rise in turnover from £548.9 million to £634.3 million for its financial year 2018-19. During this period, the revenue increase resulted in improved pre-tax profits which were recorded at £47.6 million, up from £27.6 million for the same period the previous year. Higher exchange gains on financial activities in the year also contributed to this profit level improvement.

 Northern Ireland’s Pharmaceutical Industry will Maintain Regulatory Alignment with the EU Post-Brexit

Almac Group has welcomed confirmation from the EU’s medicines regulator, the EMA, that, post-Brexit, Northern Ireland will remain in regulatory alignment with the EU, acknowledging that EU laws, in respect of medicinal products, shall continue to apply  in Northern Ireland.This offers our clients unique, unfettered and flexible access to both the UK and European markets.

Clinical Services Launches

Tempod® 1000

-Almac Clinical Services has just launched its innovative USB – Tempod 1000®– which captures and stores all clinical site temperature data thereby removing the administrative burden of updating manual temperature logs during clinical trials.

Most attractive employer index NI 2020

The Index was compiled by NIJobs.com in partnership with global employer brand specialist, Universum based on research conducted among 1476 professionals across Northern Ireland. Almac was delighted to be included in this index at number 13!